Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2009

01.06.2009 | Research Article

Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain

verfasst von: Sebastián R. Martínez Pérez, Pedro D. Armando, Andrea C. Molina Guerra, Mercé Martí Pallarés, Fernando Martínez Martínez

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives The aim of this study is to determine the influence that different risk factors (age, gender, obesity, smoking, inactivity, diabetes mellitus and previous diagnosis of arterial hypertension) have on arterial pressure, and to determine the prevalence of patients that have high blood pressure and hypertension but have not received drug-treatment for arterial hypertension. Setting 42 Spanish community pharmacies. Method Observational and descriptive study. Patients included in the study were over 18 years of age, not receiving pharmacological treatment for arterial hypertension and not pregnant. Two measurements of arterial pressure were taken from each patient on the first day of the study and two other measurements on a later day. The average of these four measurements was taken as the arterial pressure value for the patient. All measurements were taken in the participating community pharmacies, always by the pharmacist and following the same protocols. The measurements were noted in the patients’ records along with data about the seven risk factors being studied, allowing them to be related with the patient’s arterial pressure value. Results The number of patients invited to join the study was 3,760, of whom 2,574 agreed to participate, with 2,094 completing the study. It was found that an increase in the number of risk factors led to a corresponding rise in the percentage of patients with high blood pressure and arterial hypertension. The risk of having arterial hypertension was 4.23 times higher in patients aged 65 years and over. It was also 2.88 times greater in those who had been previously diagnosed with arterial hypertension, 2.79 times higher in overweight or obese patients, 2.69 times more in diabetics and 2.22 times higher in men compared with in women. Prevalence of high blood pressure in patients not receiving pharmacological treatment for arterial hypertension was 33.6%, and prevalence of arterial hypertension was 22.8%. Conclusions Of the people studied, 22.8% had arterial hypertension. For the risk factors identified, those most related to the presence of arterial hypertension were, in descending order: being 65 years old or over, previous diagnosis of arterial hypertension, being overweight or obese, being diabetic and being male.
Literatur
1.
Zurück zum Zitat Moser M. Management of hypertension, part I. Am Fam Physician. 1996;53(7):2295–302.PubMed Moser M. Management of hypertension, part I. Am Fam Physician. 1996;53(7):2295–302.PubMed
2.
Zurück zum Zitat Guidelines Committee. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. doi:10.1097/HJH.0b013e3281fc975a.CrossRef Guidelines Committee. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. doi:10.​1097/​HJH.​0b013e3281fc975a​.CrossRef
4.
Zurück zum Zitat Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. doi:10.1001/jama.289.19.2560. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. doi:10.​1001/​jama.​289.​19.​2560.
5.
Zurück zum Zitat Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Six Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 6 report. Arch Intern Med. 1997;157:2413–46. doi:10.1001/archinte.157.21.2413. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Six Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 6 report. Arch Intern Med. 1997;157:2413–46. doi:10.​1001/​archinte.​157.​21.​2413.
7.
Zurück zum Zitat Williams B, et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004––BHS IV. J Human Hypertens. 2004; 18(3): 139–85. Williams B, et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004––BHS IV. J Human Hypertens. 2004; 18(3): 139–85.
8.
Zurück zum Zitat Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125(1):36–46. doi:10.1157/13076404. Guidelines on the diagnosis and treatment of arterial hypertension in Spain 2005.CrossRef Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125(1):36–46. doi:10.​1157/​13076404. Guidelines on the diagnosis and treatment of arterial hypertension in Spain 2005.CrossRef
9.
Zurück zum Zitat De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003; 24: 1601–10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003; 24: 1601–10.
10.
Zurück zum Zitat Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004; 328: 634–40. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004; 328: 634–40.
11.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108: 2154–69. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108: 2154–69.
13.
Zurück zum Zitat Gired X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D. Estimation du nombre des sujets traités pour une HTA, una diabète ou une hyperlipidémie en France: étude FLASH 2002. Arch Mal Coeur. 2003;96:750–3. Estimation of the number of subjects treated for ATH, diabetes, or hyperlipidemia in France: FLAHS study 2002. Gired X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D. Estimation du nombre des sujets traités pour une HTA, una diabète ou une hyperlipidémie en France: étude FLASH 2002. Arch Mal Coeur. 2003;96:750–3. Estimation of the number of subjects treated for ATH, diabetes, or hyperlipidemia in France: FLAHS study 2002.
14.
Zurück zum Zitat Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157–64.PubMedCrossRef Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157–64.PubMedCrossRef
16.
Zurück zum Zitat Banegas JR, Rodríguez Artalejo F. El problema de la hipertensión arterial en España. Rev Clin Esp. 2002;202:12–5. The problem of hypertension in Spain. Banegas JR, Rodríguez Artalejo F. El problema de la hipertensión arterial en España. Rev Clin Esp. 2002;202:12–5. The problem of hypertension in Spain.
17.
Zurück zum Zitat De la Figuera M, Arnau JM, Brotons C. Hipertensión arterial en Atención Primaria. [Arterial hypertension in primary care]. Badalona: Euromedice; 2002. ISBN 84-931353-0-5. De la Figuera M, Arnau JM, Brotons C. Hipertensión arterial en Atención Primaria. [Arterial hypertension in primary care]. Badalona: Euromedice; 2002. ISBN 84-931353-0-5.
19.
Zurück zum Zitat Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D′Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure The Framingham heart study. Circulation. 2002;106:1–5.CrossRef Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D′Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure The Framingham heart study. Circulation. 2002;106:1–5.CrossRef
20.
Zurück zum Zitat Mataix J, García torres L. Hipertensión arterial. [Arterial hypertension]. En: Mataix J. Nutrición y alimentación humana. [Nutricion and human alimentation]. Madrid: Ergon; 2002. ISBN 84-8473-088-3. Mataix J, García torres L. Hipertensión arterial. [Arterial hypertension]. En: Mataix J. Nutrición y alimentación humana. [Nutricion and human alimentation]. Madrid: Ergon; 2002. ISBN 84-8473-088-3.
21.
Zurück zum Zitat Mayo Nápoles J, Pila Pérez R, Hernández Mandado P, Pila Peláez R, Guerra Rodríguez C. Hipertensión arterial en el joven: factores de riesgo. Rev Med Uruguay. 2000;16:24–30. Arterial hypertension in the young: risk factors. Mayo Nápoles J, Pila Pérez R, Hernández Mandado P, Pila Peláez R, Guerra Rodríguez C. Hipertensión arterial en el joven: factores de riesgo. Rev Med Uruguay. 2000;16:24–30. Arterial hypertension in the young: risk factors.
23.
Zurück zum Zitat Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. doi:10.1345/aph.1K311.PubMedCrossRef Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. doi:10.​1345/​aph.​1K311.PubMedCrossRef
24.
25.
Zurück zum Zitat Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother. 1993;27:555–8.PubMed Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother. 1993;27:555–8.PubMed
26.
Zurück zum Zitat Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic. Am J Hosp Pharm. 1992;49:1681–8.PubMed Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic. Am J Hosp Pharm. 1992;49:1681–8.PubMed
27.
Zurück zum Zitat Expert Panel on the Identification. Evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults; Executive summary. Am J Clin Nutr. 1998;68:899–917. Expert Panel on the Identification. Evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults; Executive summary. Am J Clin Nutr. 1998;68:899–917.
28.
Zurück zum Zitat Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el Estudio de la Obesidad (SEEDO). Med Clin (Barc). 2000;115:587–97. Consensus SEEDO’2000 for the evaluation of overweight and obese people, and the establishment of therapeutic intervention. Spanish Society for the Study of Obesity (SEEDO). Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el Estudio de la Obesidad (SEEDO). Med Clin (Barc). 2000;115:587–97. Consensus SEEDO’2000 for the evaluation of overweight and obese people, and the establishment of therapeutic intervention. Spanish Society for the Study of Obesity (SEEDO).
31.
Zurück zum Zitat Martínez Pérez SR, Sánchez Alonso FJ, Baena Parejo MI. Efectos de la intervención farmacéutica en pacientes con presión arterial elevada sin tratamiento farmacológico. Seguim Farmacoter. 2004;2(3):181–8. Effects of pharmaceutical intervention in patients with high blood pressure without pharmacological treatment. Martínez Pérez SR, Sánchez Alonso FJ, Baena Parejo MI. Efectos de la intervención farmacéutica en pacientes con presión arterial elevada sin tratamiento farmacológico. Seguim Farmacoter. 2004;2(3):181–8. Effects of pharmaceutical intervention in patients with high blood pressure without pharmacological treatment.
32.
Zurück zum Zitat Carrión Valero L, Carballo Herencia JA, Divisón Garrote JA, Massó Orozco J, Artigao Rodenas LM, Sanchís Domenech C, et al. La oficina de farmacia puede mejorar el grado de conocimiento de la hipertensión arterial. Hipertension. 2002;19(7):299–304. Community pharmacies could improve awareness on arterial hypertension. Carrión Valero L, Carballo Herencia JA, Divisón Garrote JA, Massó Orozco J, Artigao Rodenas LM, Sanchís Domenech C, et al. La oficina de farmacia puede mejorar el grado de conocimiento de la hipertensión arterial. Hipertension. 2002;19(7):299–304. Community pharmacies could improve awareness on arterial hypertension.
33.
Zurück zum Zitat Velázquez MO, Lara EA, Martínez MMY, Márquez FF. La detección integrada como un instrumento para vincular la prevención primaria, el tratamiento temprano y la vigilancia epidemiológica en diabetes e hipertensión arterial. Rev Endocrinol Nutr. 2000;8(4):129–35. Detection integrated as an instrument linked to primary care, early treatment and epidemiological vigilance in diabetes and arterial hypertension. Velázquez MO, Lara EA, Martínez MMY, Márquez FF. La detección integrada como un instrumento para vincular la prevención primaria, el tratamiento temprano y la vigilancia epidemiológica en diabetes e hipertensión arterial. Rev Endocrinol Nutr. 2000;8(4):129–35. Detection integrated as an instrument linked to primary care, early treatment and epidemiological vigilance in diabetes and arterial hypertension.
34.
Zurück zum Zitat Martínez Pérez SR, Sánchez Alonso FJ. Determinación de factores de riesgo en pacientes con diferentes valores de presión arterial. Pharm Care Esp. 2006;8(5):200–8. Determination of risk factors en patients with different values of arterial pressure. Martínez Pérez SR, Sánchez Alonso FJ. Determinación de factores de riesgo en pacientes con diferentes valores de presión arterial. Pharm Care Esp. 2006;8(5):200–8. Determination of risk factors en patients with different values of arterial pressure.
39.
40.
Zurück zum Zitat Park JJ, Nelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting: drug therapy monitoring and counselling by pharmacists contributed to improved blood pressure control in study patients. J Am Pharm Assoc. 1996;36:443–51. Park JJ, Nelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting: drug therapy monitoring and counselling by pharmacists contributed to improved blood pressure control in study patients. J Am Pharm Assoc. 1996;36:443–51.
Metadaten
Titel
Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain
verfasst von
Sebastián R. Martínez Pérez
Pedro D. Armando
Andrea C. Molina Guerra
Mercé Martí Pallarés
Fernando Martínez Martínez
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2009
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9267-7

Weitere Artikel der Ausgabe 3/2009

International Journal of Clinical Pharmacy 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.